368 related articles for article (PubMed ID: 26075455)
21. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
22. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
[TBL] [Abstract][Full Text] [Related]
23. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
24. Riolan's muscle: action and indications for botulinum toxin injection.
Mackie IA
Eye (Lond); 2000 Jun; 14 ( Pt 3A)():347-52. PubMed ID: 11026998
[TBL] [Abstract][Full Text] [Related]
25. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Cakmur R; Ozturk V; Uzunel F; Donmez B; Idiman F
J Neurol; 2002 Jan; 249(1):64-8. PubMed ID: 11954870
[TBL] [Abstract][Full Text] [Related]
26. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
[TBL] [Abstract][Full Text] [Related]
27. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
29. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
[TBL] [Abstract][Full Text] [Related]
30. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
31. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
33. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Isshiki Y; Ishikawa H; Mimura O
Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
[TBL] [Abstract][Full Text] [Related]
34. Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm.
Romero-Caballero MD; Miralles de Imperial-Ollero JA; Sarabia-Marín E; Villegas-Pérez MP
Int Ophthalmol; 2023 Aug; 43(8):2731-2736. PubMed ID: 37185774
[TBL] [Abstract][Full Text] [Related]
35. [Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm].
Lasalvia CG; Pereira Lde S; da Cunha MC; Kitadai SP
Arq Bras Oftalmol; 2006; 69(5):701-5. PubMed ID: 17187139
[TBL] [Abstract][Full Text] [Related]
36. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
[No Abstract] [Full Text] [Related]
37. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Jost WH; Kohl A
J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
[TBL] [Abstract][Full Text] [Related]
38. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
[TBL] [Abstract][Full Text] [Related]
39. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
40. Lid wiper epitheliopathy in patients with blepharospasm and/or hemifacial spasm.
Romero-Caballero MD; Salmerón Ato MP; Palazón-Cabanes A; Caravaca-Alegría A
Arch Soc Esp Oftalmol (Engl Ed); 2022 Jul; 97(7):376-380. PubMed ID: 35292220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
